Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal Dysfunction

NCT ID: NCT00818701

Last Updated: 2010-09-24

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 1 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-02-28
• Study Completion Date: 2010-08-31

Brief Summary

The purpose of the study is to show that low dose recombinant BNP coupled with phosphodiesterase V inhibition will improve renal dysfunction and promote relief of volume overload in patinets with acute decompensated heart failure complicated by the cardiorenal syndrome.

Detailed Description

Renal dysfunction is a common comorbidity, as well as a common and progressive complication, of heart failure (HF). Increasingly, the clinical syndrome of HF is one of "cardiorenal" failure owing to the frequent presentation of combined cardiac and renal dysfunction. Recent studies have established the prognostic importance of renal dysfunction in patients with chronic HF. An analysis of the patients in the second prospective randomized study of Ibopamine on mortality and efficacy (PRIME) by Hillege et al1 demonstrated that estimated glomerular filtration rate (GFR) is the most powerful predictor of mortality, exceeding functional status and ejection fraction (EF).

In an ongoing prospective study, we are assessing the neurohumoral and renal hemodynamic profile of hospitalized patients with ADHF who do or do not develop the CRS. Our preliminary findings suggest that indeed the combination of pronounced activation of renin-angiotensin-aldosterone system (RAAS), decreased renal perfusion pressure and importantly, a relative deficiency of the natriuretic peptides (despite marked volume overload) predisposes to the development of CRS.

Conditions

Congestive Heart Failure; Renal Dysfunction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

1: low dose BNP alone

low dose BNP with placebo

Group Type: PLACEBO_COMPARATOR

low dose Nesiritide

Intervention Type: DRUG

Nesiritide infusion 0.005ug/kg/min

2: low dose BNP + PDEVI

low dose BNpo + PDEVI

Group Type: ACTIVE_COMPARATOR

nesiritide, Sildenafil

Intervention Type: DRUG

Nesiritide 0.005ug/kg/min Sildenafil 50 mg

Interventions

low dose Nesiritide

Nesiritide infusion 0.005ug/kg/min

Intervention Type: DRUG

nesiritide, Sildenafil

Nesiritide 0.005ug/kg/min Sildenafil 50 mg

Intervention Type: DRUG

Other Intervention Names

Natracor; Natrecor; Viagra

Eligibility Criteria

Inclusion Criteria

• Left ventricular ejection fraction 35% assessed by echocardiography, nuclear scan or left ventriculogram within the past 2 years
• Stable (NYHA) class II and III symptoms as defined by:

1. no change in NYHA symptoms over the past 3 months;

2. on stable doses of ACE inhibitor and beta blocker for one month;

3. no episode of decompensated CHF over the past 3 months.

• Calculated creatinine clearance of equal or less than 60 ml/min and greater than 30 ml/min, using the Cockcroft-Gault formula assessed within the past 12 months

Exclusion Criteria

• Nitrates or alpha blockers
• Prior diagnosis of intrinsic renal diseases including renal artery stenosis of > 50%
• Peritoneal or hemodialysis within 90 days or anticipation that dialysis or ultrafiltration of any form will be required during the study period
• Hospitalization for decompensated CHF during the past 3 months
• Myocardial infarction within 3 months of screening
• Unstable angina within 3 months of screening or any evidence of myocardial ischemia
• Significant valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, or biopsy proven active myocarditis
• Severe congenital heart diseases
• Sustained ventricular tachycardia or ventricular fibrillation within 14 days of screening
• Second or third degree heart block without a permanent cardiac pacemaker
• Stroke within 3 months of screening or other evidence of significantly compromised CNS perfusion
• Serum sodium of < 125 mEq/dL or > 150 mEq/dL
• Serum potassium of < 3.5 mEq/dL or > 5.7 mEq/dL
• Hemoglobin < 10 gm/dl
• Other acute or chronic medical conditions or laboratory abnormality which may increase the risks associated with study participation or may interfere with interpretation of the data
• Received an investigational drug within 1 month prior to dosing
• Patients with an allergy to iodine.
• Female subject who is pregnant or breastfeeding

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mayo Clinic

OTHER

Sponsor Role: lead

Responsible Party

Mayo Clinc

Principal Investigators

Horng H Chen, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Mayo Clinic

Rochester, Minnesota, United States

Mayo Clinic

Rochester, Minnesota, United States

Countries

United States

Other Identifiers

BNP + PDEVI

Identifier Type: -

Identifier Source: secondary_id

08-004797

Identifier Type: -

Identifier Source: org_study_id